UroMems Appoints Dan Rose as New Chairman of the Supervisory Board

UroMems Welcomes a New Leader

UroMems, the international medical technology firm known for its groundbreaking UroActive® device, has officially welcomed Dan Rose as the new chairman of its supervisory board. This appointment comes during a crucial time as the company prepares to embark on pivotal clinical trials in the United States and Europe for its innovative automated artificial urinary sphincter designed to treat stress urinary incontinence (SUI).

According to Hamid Lamraoui, co-founder and CEO of UroMems, the company is excited about Rose's leadership. "We are thrilled to welcome Dan as our new board chairman at such a significant juncture in our journey. His extensive experience in the medical device industry will be invaluable as we advance UroActive® into the next phase of large-scale clinical trials, setting the stage for the commercial launch of our first smart, automated implant for treating SUI."

Dan Rose brings more than 25 years of specialized expertise in medical devices to the role. Currently, he is the CEO of Endovascular Engineering, a Silicon Valley firm focused on treating venous thromboembolism. Previously, he held the position of CEO at LimFlow S.A., a company that pioneered limb care for patients suffering from chronic ischemia, a condition that can lead to amputation. Having played a significant role in LimFlow's success, he was instrumental in its acquisition by Inari Medical for a notable $415 million. Before LimFlow, Rose held leadership positions at organizations like Direct Flow Medical, Sequana Medical AG, and Medtronic. He holds a bachelor’s and master’s degree in humanities from the University of Virginia, as well as an MBA from the Darden School of Business.

In expressing his enthusiasm regarding his new position, Dan Rose stated, "I am honored to take on this role and potentially make a tangible impact on the quality of life for millions suffering from stress urinary incontinence. I have been genuinely impressed by the momentum UroMems has achieved and look forward to guiding its patient-centered technology into its next phase."

UroMems has made significant strides in research and development, clinical outcomes, and organizational setup, recently securing €44 million following remarkably positive results from multicentric pilot clinical studies.

Stress urinary incontinence affects around 40 million Americans and 90 million Europeans. This condition can severely impact individuals' quality of life, often resulting in depressive symptoms, low self-esteem, and social stigma.

About UroActive

The innovative UroActive platform technology, patented with over 150 patents, aims to redefine the limits of existing solutions. It optimizes safety, performance, patient experience, and surgical convenience. UroActive is recognized as the first active, implantable electronic artificial urinary sphincter designed to compensate for sphincter insufficiency in both men and women suffering from SUI. It employs a unique mechatronic platform utilizing smart, digital, and robotic systems integrated into the device.

As of now, UroActive has not received FDA marketing authorization and is not available for sale in the United States or the EU. For further details, please visit www.uromems.com.